For research use only.
| Verified Samples |
Verified Samples in WB: 293T, HepG2, K562, HT29, A549, Raji Verified Samples in IHC: Human thyroid cancer, Human ovarian cancer |
| Dilution | WB 1:1000-1:5000, IHC 1:50-1:300 |
| Clonality | Polyclonal |
| Immunogen | Fusion protein of human RUVBL1 |
| Abbre | RUVBL1 |
| Synonyms | 54-KD, 49 kDa TATA box binding protein interacting protein, 49 kDa TATA box-binding protein-interacting protein, 49 kDa TBP interacting protein , 49 kDa TBP-interacting protein, 54 kDa erythrocyte cytosolic protein, ECP-54, ECP54, ERYTHROCYTE CYTOSOLIC PROTEIN, I |
| Swissprot | |
| Calculated MW | 50 kDa |
| Observed MW |
Refer to figures
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Nucleus matrix. Nucleus>nucleoplasm. Cytoplasm. Membrane. Cytoplasm>cytoskeleton>centrosome. Mainly localized in the nucleus, associated with nuclear matrix or in the nuclear cytosol, although it is also present in the cytoplasm and associated with the cell membranes. In prophase and prometaphase it is located at the centrosome and the branching microtubule spindles. After mitotic nuclear membrane disintigration it accumulates at the centrosome and sites of tubulin polymerization. As cells pass through metaphase and into telophase it is located close to the centrosome at the early phase of tubulin polymerization. In anaphase it accumulates at the zone of tubule interdigitation. In telophase it is found at polar tubule overlap, and it reappears at the site of chromosomal decondensation in the daughter cells. |
| Concentration | 1.14 mg/mL |
| Buffer | PBS with 0.05% NaN3 and 40% Glycerol,pH7.4 |
| Purification Method | Antigen affinity purification |
| Research Areas | Cancer, Epigenetics and Nuclear Signaling |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended. |
| background | This gene encodes a protein that has both DNA-dependent ATPase and DNA helicase activities and belongs to the ATPases associated with diverse cellular activities (AAA+) protein family. The encoded protein associates with several multisubunit transcriptional complexes and with protein complexes involved in both ATP-dependent remodeling and histone modification. Alternate splicing results in multiple transcript variants. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
{{item.title}}
IF：{{item.impact}}
Journal：{{item.journal}}
DOI：{{item.doi}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
{{item.content}}
